Innoviva, Inc. (NASDAQ:INVA) traded at $9.94 at last check on Friday, Oct 16, making a downturn move of -0.5% on its previous day’s price.

Looking at the stock we see that its previous close was $9.99 and the beta (5Y monthly) reads 0.66 with the day’s price range being $9.89 – 10.05. The company has a 12-month trailing PE ratio of 4.9. In terms of its 52-week price range, INVA has a high of $15.62 and a low of $7.58. The company’s stock has gained about -14.38% over that past 30 days.

Analysts tracking the company’s growth have also given it a consensus growth in revenue estimated at $66.6 Million, with a low of $66.6 Million and a high of $66.6 Million. The median projection represents growth adding up to 7.9% compared to sales earnings for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecasts for 2020 are expected to hit $235.07 Million, or -9.9% down from figures reported last year.

On the other hand, looking at the outlook for the INVA stock, short term indicators assign the stock an average of 100% Sell, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 1 analysts where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, none have rated the Innoviva, Inc. (INVA) stock as a Hold, while none rate it as a Buy. None analysts rate it as outperform while none of them rated it as underperform, whereas 1 suggests the stock as a Sell. The stock has an overall rating of Sell and investors could take advantage and scoop up stock of the company.

Looking further, we note that the PEG ratio for the INVA stock currently stands at 0.25, and the current price level is -6.38% off its SMA20 and -14.87% from its 50-day simple moving average. The RSI (14) is pointing at 32.05 while the volatility over the past week is 3.2% and jumps to 3.47% over the past one month. The beta value is 0.66, while the average true range (ATR) is currently pointing at 0.38. The average price target for the stock over the next 12 months is $8, with the estimates having a low of $8 and a high of $8. These price ends are -19.52% and -19.52% off the current price level respectively, although investors could be excited at the prospect of a -19.52% if the INVA share price touches on the median price of $8.

Let’s briefly compare Innoviva, (INVA) stock to its peers. We find that today’s price change of -0.5% and -9.06% over the past 12 months for INVA competes that of Johnson & Johnson (JNJ), which has seen its stock price rise 0.62% in the latest trading session and is +8.76% over the last one year. Another of its peers Pfizer Inc (PFE) has climbed 3.83% today, and is +4.09% up over the past year, while Merck & Company (MRK) is also down -0.5% yet its price remains in the red at -9.06% over the same period. Johnson has a P/E ratio of 26.57 compared to Innoviva,’s 4.9 and Pfizer’s 15.45. In contrast to these companies, both the S&P 500 Index and the Dow Jones Industrial are today at 0.01% and 0.39%, respectively, in early deals.

Coming back to Innoviva, Inc. (NASDAQ:INVA), we note that the average 3-month trading volume was 736.77 Million, while that of the preceding 10-day period stands at 552.2 Million. Current shares outstanding are 101.39 Million.

According to data from Thomson Reuters, insiders hold 32.33% of the company’s shares while institutions hold 76.37%. The data shows that short shares as of September 29, 2020, stood at 11.19 Million at a short ratio of 13.17. This represents a 11.04% Short interest in Shares outstanding on September 29, 2020. Shares short dropped in September from the previous month at 12.72 Million. Investors should be excited about this stock as its upside potential is great, with today’s price pushing the stock -29.8% down in year-to-date price movement.